{ "confidence": "provisional", "diagnostics": { "counterfactual_support": { "best": {}, "context_tense": 0, "count": 0, "overlap_stable": 0, "rows": [] }, "focus_context": "corpus", "focus_context_gluing": { "checks": 18, "compatible": 18, "max_loss": 0.0688183982493118, "max_section_gap": 0.07687343379331082, "rows": [ { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.07390437925312127, "gradient_suggestions": [ { "direction": "increase", "latent_dim": 7, "magnitude": 0.35355339059327373, "section": "", "section_loss": 0.07687343379331082 }, { "direction": "increase", "latent_dim": 7, "magnitude": 0.35355339059327373, "section": "daraxonrasib_s_manageable_side_effects|influences|the_development_of_daraxonrasib_to_balance_efficacy_and_tolerability_causing_side_effects_to_remain_manageable_in_patients", "section_loss": 0.07588066757993917 }, { "direction": "increase", "latent_dim": 7, "magnitude": 0.35355339059327373, "section": "daraxonrasib_s_manageable_side_effects|leads_to|manageable_side_effects_during_treatment", "section_loss": 0.0689590363861138 } ], "max_section_gap": 0.07687343379331082, "overlap_confidence": 0.9311816017506882, "overlap_sections": 3, "projection_dim": 8, "source_context": "corpus", "target_context": "daraxonrasib_s_manageable_side_effects", "weighted_glue_loss": 0.0688183982493118 }, { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.051428832960228085, "gradient_suggestions": [ { "direction": "increase", "latent_dim": 2, "magnitude": 0.3535533905932737, "section": "", "section_loss": 0.05834380951585417 }, { "direction": "increase", "latent_dim": 2, "magnitude": 0.3494660681586694, "section": "innovative_drug_screening_methods|leads_to|the_identification_of_daraxonrasib_molecules_that_bind_specifically_to_kras_proteins", "section_loss": 0.05523784762827579 }, { "direction": "increase", "latent_dim": 2, "magnitude": 0.3494660681586694, "section": "innovative_drug_screening_methods|leads_to|the_inhibition_of_the_kras_protein_which_reduces_tumor_growth_in_pancreatic_cancer_patients", "section_loss": 0.05007052570713651 }, { "direction": "increase", "latent_dim": 2, "magnitude": 0.34946606815866943, "section": "innovative_drug_screening_methods|increases|survival_in_pancreatic_cancer_patients", "section_loss": 0.04206314898964586 } ], "max_section_gap": 0.05834380951585417, "overlap_confidence": 0.951086719949049, "overlap_sections": 4, "projection_dim": 8, "source_context": "corpus", "target_context": "innovative_drug_screening_methods", "weighted_glue_loss": 0.04891328005095087 }, { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.04841208684627692, "gradient_suggestions": [ { "direction": "increase", "latent_dim": 4, "magnitude": 0.3760336639835975, "section": "daraxonrasib_drug_development|leads_to|tumor_shrinkage_and_improved_patient_survival", "section_loss": 0.05737334144512382 }, { "direction": "increase", "latent_dim": 4, "magnitude": 0.38012098641820175, "section": "", "section_loss": 0.051901131288493864 }, { "direction": "increase", "latent_dim": 4, "magnitude": 0.37603366398359744, "section": "daraxonrasib_drug_development|increases|survival_in_pancreatic_cancer_patients", "section_loss": 0.04266027979180355 }, { "direction": "increase", "latent_dim": 4, "magnitude": 0.37603366398359744, "section": "daraxonrasib_drug_development|leads_to|the_inhibition_of_the_kras_protein_which_reduces_uncontrolled_cell_growth_in_pancreatic_cancer_cells", "section_loss": 0.041713594859686426 } ], "max_section_gap": 0.05737334144512382, "overlap_confidence": 0.953823417858616, "overlap_sections": 4, "projection_dim": 8, "source_context": "corpus", "target_context": "daraxonrasib_drug_development", "weighted_glue_loss": 0.046176582141383996 }, { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.04184364802254223, "gradient_suggestions": [ { "direction": "increase", "latent_dim": 5, "magnitude": 0.3596843742451802, "section": "daraxonrasib_clinical_trial_outcomes|leads_to|inhibition_of_the_kras_protein_which_reduces_cancer_progression_by_causing_tumor_shrinkage", "section_loss": 0.048757986493961625 }, { "direction": "increase", "latent_dim": 5, "magnitude": 0.3596843742451802, "section": "daraxonrasib_clinical_trial_outcomes|increases|patient_survival_by_selectively_killing_cancer_cells_while_sparing_normal_tissue", "section_loss": 0.04205230155813201 }, { "direction": "increase", "latent_dim": 5, "magnitude": 0.3596843742451802, "section": "", "section_loss": 0.04145435864880215 }, { "direction": "increase", "latent_dim": 5, "magnitude": 0.35968437424518024, "section": "daraxonrasib_clinical_trial_outcomes|causes|tumor_shrinkage_in_pancreatic_cancer_patients_with_kras_mutations", "section_loss": 0.035109945389273124 } ], "max_section_gap": 0.048757986493961625, "overlap_confidence": 0.9598369216897727, "overlap_sections": 4, "projection_dim": 8, "source_context": "corpus", "target_context": "daraxonrasib_clinical_trial_outcomes", "weighted_glue_loss": 0.04016307831022728 }, { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.03831823278054357, "gradient_suggestions": [ { "direction": "increase", "latent_dim": 0, "magnitude": 0.2663571786550482, "section": "potential_applications_in_lung_and_colon_cancers|reduces|uncontrolled_cell_growth_in_colon_cancer", "section_loss": 0.04928864052331256 }, { "direction": "increase", "latent_dim": 0, "magnitude": 0.2663571786550482, "section": "potential_applications_in_lung_and_colon_cancers|causes|tumor_shrinkage_and_improves_patient_survival_in_lung_cancer", "section_loss": 0.03575893503513871 }, { "direction": "increase", "latent_dim": 0, "magnitude": 0.2663571786550482, "section": "", "section_loss": 0.03495146847539175 }, { "direction": "increase", "latent_dim": 4, "magnitude": 0.25818253378583955, "section": "potential_applications_in_lung_and_colon_cancers|leads_to|the_inhibition_of_the_kras_protein_in_lung_cancer_patients_with_kras_mutations_which_reduces_uncontrolled_cell_growth", "section_loss": 0.03327388708833127 } ], "max_section_gap": 0.04928864052331256, "overlap_confidence": 0.9630958683274491, "overlap_sections": 4, "projection_dim": 8, "source_context": "corpus", "target_context": "potential_applications_in_lung_and_colon_cancers", "weighted_glue_loss": 0.03690413167255093 }, { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.03822298421078032, "gradient_suggestions": [ { "direction": "decrease", "latent_dim": 2, "magnitude": 0.35355339059327373, "section": "overcoming_decades_of_drug_discovery_failures|leads_to|tumor_shrinkage_and_extended_survival_in_pancreatic_cancer_patients", "section_loss": 0.043784236118072015 }, { "direction": "decrease", "latent_dim": 2, "magnitude": 0.3535533905932737, "section": "", "section_loss": 0.04343131754411365 }, { "direction": "decrease", "latent_dim": 2, "magnitude": 0.3535533905932737, "section": "overcoming_decades_of_drug_discovery_failures|leads_to|uncontrolled_cell_growth", "section_loss": 0.042600879952925615 }, { "direction": "decrease", "latent_dim": 2, "magnitude": 0.3535533905932737, "section": "overcoming_decades_of_drug_discovery_failures|increases|cancer_progression_by_driving_continuous_tumor_cell_proliferation", "section_loss": 0.023075503228009983 } ], "max_section_gap": 0.043784236118072015, "overlap_confidence": 0.9631842245913712, "overlap_sections": 4, "projection_dim": 8, "source_context": "corpus", "target_context": "overcoming_decades_of_drug_discovery_failures", "weighted_glue_loss": 0.03681577540862867 }, { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.019170369875371712, "gradient_suggestions": [ { "direction": "increase", "latent_dim": 2, "magnitude": 0.23161493796091148, "section": "pancreatic_lung_and_colon_cancer_linkage|increases|survival_rates_in_patients_with_kras_mutant_pancreatic_lung_and_colon_cancers_by_selectively_killing_cancer_cells_while_sparing_normal_tissue", "section_loss": 0.021651705332249284 }, { "direction": "increase", "latent_dim": 2, "magnitude": 0.23161493796091148, "section": "pancreatic_lung_and_colon_cancer_linkage|reduces|tumor_growth_by_binding_to_the_kras_protein_and_inhibiting_its_permanently_active_state_caused_by_kras_mutations", "section_loss": 0.021533369715734645 }, { "direction": "increase", "latent_dim": 2, "magnitude": 0.23161493796091148, "section": "pancreatic_lung_and_colon_cancer_linkage|leads_to|uncontrolled_cell_growth_and_cancer_progression_in_pancreatic_lung_and_colon_cancers", "section_loss": 0.020823356016646803 }, { "direction": "increase", "latent_dim": 4, "magnitude": 0.144418726022686, "section": "", "section_loss": 0.012673048436856113 } ], "max_section_gap": 0.021651705332249284, "overlap_confidence": 0.9811902205538844, "overlap_sections": 4, "projection_dim": 8, "source_context": "corpus", "target_context": "pancreatic_lung_and_colon_cancer_linkage", "weighted_glue_loss": 0.01880977944611551 }, { "compatible": true, "construction": "random_projection_psr_sheaf_v1", "glue_loss": 0.016753156286764152, "gradient_suggestions": [ { "direction": "decrease", "latent_dim": 4, "magnitude": 0.20401070238807648, "section": "patient_tumor_shrinkage_and_survival|leads_to|uncontrolled_cell_growth_and_cancer_progression", "section_loss": 0.019171771270140837 }, { "direction": "decrease", "latent_dim": 4, "magnitude": 0.2040107023880765, "section": "patient_tumor_shrinkage_and_survival|reduces|the_risk_of_ineffective_treatment_continuation_thereby_increasing_the_likelihood_of_prolonged_patient_survival_during_daraxonrasib_therapy", "section_loss": 0.01877522392156711 }, { "direction": "decrease", "latent_dim": 4, "magnitude": 0.20401070238807648, "section": "patient_tumor_shrinkage_and_survival|leads_to|increased_survival_in_pancreatic_cancer_patients", "section_loss": 0.0186566422385531 }, { "direction": "decrease", "latent_dim": 4, "magnitude": 0.20401070238807648, "section": "patient_tumor_shrinkage_and_survival|increases|the_ability_to_monitor_patient_responses_to_daraxonrasib_thereby_affecting_clinical_decisions_on_treatment_continuation_or_adjustment", "section_loss": 0.01858523821437262 }, { "direction": "decrease", "latent_dim": 4, "magnitude": 0.20401070238807648, "section": "patient_tumor_shrinkage_and_survival|increases|overall_survival_rates_in_these_patients", "section_loss": 0.01820144158440255 }, { "direction": "decrease", "latent_dim": 4, "magnitude": 0.20401070238807648, "section": "patient_tumor_shrinkage_and_survival|leads_to|extended_patient_survival", "section_loss": 0.01820144158440255 } ], "max_section_gap": 0.019171771270140837, "overlap_confidence": 0.9835228873565068, "overlap_sections": 21, "projection_dim": 8, "source_context": "corpus", "target_context": "patient_tumor_shrinkage_and_survival", "weighted_glue_loss": 0.016477112643493094 } ], "tense": 0 }, "focus_context_restrictions": { "checks": 18, "compatible": 11, "max_gap": 0.5971098265895953, "rows": [ { "compatible": false, "max_abs_gap": 0.5971098265895953, "mean_abs_gap": 0.3291586384071933, "shared_cells": 9, "source_context": "corpus", "target_context": "daraxonrasib_s_manageable_side_effects" }, { "compatible": false, "max_abs_gap": 0.49710982658959535, "mean_abs_gap": 0.2460260115606936, "shared_cells": 16, "source_context": "corpus", "target_context": "daraxonrasib_clinical_trial_outcomes" }, { "compatible": false, "max_abs_gap": 0.49710982658959535, "mean_abs_gap": 0.2460260115606936, "shared_cells": 16, "source_context": "corpus", "target_context": "daraxonrasib_drug_development" }, { "compatible": false, "max_abs_gap": 0.49710982658959535, "mean_abs_gap": 0.2460260115606936, "shared_cells": 16, "source_context": "corpus", "target_context": "innovative_drug_screening_methods" }, { "compatible": false, "max_abs_gap": 0.49710982658959535, "mean_abs_gap": 0.2460260115606936, "shared_cells": 16, "source_context": "corpus", "target_context": "overcoming_decades_of_drug_discovery_failures" }, { "compatible": false, "max_abs_gap": 0.49710982658959535, "mean_abs_gap": 0.2460260115606936, "shared_cells": 16, "source_context": "corpus", "target_context": "pancreatic_lung_and_colon_cancer_linkage" }, { "compatible": false, "max_abs_gap": 0.49710982658959535, "mean_abs_gap": 0.2460260115606936, "shared_cells": 16, "source_context": "corpus", "target_context": "potential_applications_in_lung_and_colon_cancers" }, { "compatible": true, "max_abs_gap": 0.1939655172413793, "mean_abs_gap": 0.04682280247159616, "shared_cells": 400, "source_context": "corpus", "target_context": "kras_protein_as_cancer_growth_driver" } ], "tense": 7 }, "focus_context_support": { "context_id": "corpus", "history_count": 344, "rank": 332, "test_count": 344, "top_histories": [ "", "breakthrough_in_cancer_drug_development|causes|tumor_shrinkage_in_pancreatic_cancer_patients_with_kras_mutations", "breakthrough_in_cancer_drug_development|increases|cancer_progression_by_continuously_driving_tumor_growth", "breakthrough_in_cancer_drug_development|increases|cancer_progression_without_targeted_inhibition", "breakthrough_in_cancer_drug_development|increases|pancreatic_cancer_progression", "breakthrough_in_cancer_drug_development|increases|pancreatic_tumor_growth", "breakthrough_in_cancer_drug_development|increases|patient_survival", "breakthrough_in_cancer_drug_development|increases|patient_survival_by_selectively_killing_cancer_cells_while_sparing_normal_tissue" ], "top_tests": [ "breakthrough_in_cancer_drug_development|causes|tumor_shrinkage_in_pancreatic_cancer_patients_with_kras_mutations", "breakthrough_in_cancer_drug_development|increases|cancer_progression_by_continuously_driving_tumor_growth", "breakthrough_in_cancer_drug_development|increases|cancer_progression_without_targeted_inhibition", "breakthrough_in_cancer_drug_development|increases|pancreatic_cancer_progression", "breakthrough_in_cancer_drug_development|increases|pancreatic_tumor_growth", "breakthrough_in_cancer_drug_development|increases|patient_survival", "breakthrough_in_cancer_drug_development|increases|patient_survival_by_selectively_killing_cancer_cells_while_sparing_normal_tissue", "breakthrough_in_cancer_drug_development|increases|survival_in_cancer_patients_by_selectively_inhibiting_kras_protein_activity" ] }, "topos_summary": { "compatible_gluing_overlaps": 18, "compatible_restrictions": 11, "context_event_counts": { "breakthrough_in_cancer_drug_development": 39, "breakthrough_in_pancreatic_cancer_treatment": 42, "challenges_in_targeting_kras_protein": 24, "challenges_targeting_kras_protein": 29, "daraxonrasib_clinical_trial_outcomes": 4, "daraxonrasib_drug_development": 4, "daraxonrasib_extends_pancreatic_cancer_survival": 35, "daraxonrasib_s_manageable_side_effects": 3, "daraxonrasib_targeting_kras_protein": 36, "innovative_drug_screening_methods": 4, "kras_gene_mutations_and_cancer": 22, "kras_protein_as_cancer_growth_driver": 22, "metastatic_pancreatic_cancer_treatment": 32, "molecular_screening_for_kras_binding": 30, "overcoming_decades_of_drug_discovery_failures": 4, "pancreatic_lung_and_colon_cancer_linkage": 4, "patient_tumor_shrinkage_and_survival": 22, "potential_applications_in_lung_and_colon_cancers": 4 }, "counterfactual_count": 0, "directness_counts": { "claim_path:breakthrough_in_cancer_drug_development": 4, "claim_path:breakthrough_in_cancer_drug_development/advances_in_immunotherapy_drug_design": 4, "claim_path:breakthrough_in_cancer_drug_development/breakthroughs_in_car_t_cell_therapy_drugs": 4, "claim_path:breakthrough_in_cancer_drug_development/clinical_trial_innovations_for_faster_drug_approval": 4, "claim_path:breakthrough_in_cancer_drug_development/combination_therapies_synergizing_chemotherapy_and_immunotherapy": 4, "claim_path:breakthrough_in_cancer_drug_development/development_of_targeted_kinase_inhibitors": 4, "claim_path:breakthrough_in_cancer_drug_development/nanotechnology_applications_in_cancer_drug_delivery": 4, "claim_path:breakthrough_in_cancer_drug_development/novel_molecular_targets_identified_for_cancer_therapy": 4, "claim_path:breakthrough_in_cancer_drug_development/overcoming_drug_resistance_in_cancer_treatment": 4, "claim_path:breakthrough_in_cancer_drug_development/role_of_personalized_medicine_in_cancer_drug_development": 3, "claim_path:breakthrough_in_pancreatic_cancer_treatment": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/advances_in_immunotherapy_approaches": 3, "claim_path:breakthrough_in_pancreatic_cancer_treatment/clinical_trial_breakthroughs_and_new_drug_approvals": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/development_of_early_detection_biomarkers": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/impact_of_combination_chemotherapy_regimens": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/innovations_in_surgical_techniques_and_outcomes": 3, "claim_path:breakthrough_in_pancreatic_cancer_treatment/integration_of_artificial_intelligence_in_treatment_planning": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/novel_targeted_therapies_for_pancreatic_cancer": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/overcoming_drug_resistance_mechanisms": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/role_of_genetic_profiling_in_personalized_treatment": 4, "claim_path:breakthrough_in_pancreatic_cancer_treatment/use_of_nanotechnology_for_drug_delivery": 4, "claim_path:challenges_in_targeting_kras_protein": 4, "claim_path:challenges_in_targeting_kras_protein/challenges_in_delivering_therapeutics_effectively_to_kras_driven_tumors": 3, "claim_path:challenges_in_targeting_kras_protein/development_of_drug_resistance_mechanisms_in_kras_mutant_cancers": 2, "claim_path:challenges_in_targeting_kras_protein/genetic_heterogeneity_and_mutation_specific_targeting_challenges": 3, "claim_path:challenges_in_targeting_kras_protein/high_affinity_of_kras_for_gtp_gdp_molecules": 4, "claim_path:challenges_in_targeting_kras_protein/intracellular_localization_and_membrane_association_of_kras": 3, "claim_path:challenges_in_targeting_kras_protein/structural_complexity_and_conformational_flexibility_of_kras_protein": 1, "claim_path:challenges_in_targeting_kras_protein/toxicity_and_off_target_effects_of_kras_targeted_therapies": 4, "claim_path:challenges_targeting_kras_protein": 4, "claim_path:challenges_targeting_kras_protein/challenges_in_delivering_kras_targeting_agents_into_tumor_cells": 4, "claim_path:challenges_targeting_kras_protein/functional_redundancy_and_compensatory_signaling_pathways": 3, "claim_path:challenges_targeting_kras_protein/intratumoral_heterogeneity_impacting_kras_targeted_therapy_efficacy": 3, "claim_path:challenges_targeting_kras_protein/lack_of_well_defined_druggable_pockets_on_kras_surface": 4, "claim_path:challenges_targeting_kras_protein/limitations_of_current_screening_methods_for_kras_inhibitors": 4, "claim_path:challenges_targeting_kras_protein/off_target_effects_and_toxicity_associated_with_kras_inhibitors": 3, "claim_path:challenges_targeting_kras_protein/resistance_mechanisms_to_kras_inhibitors_in_cancer_cells": 3, "claim_path:challenges_targeting_kras_protein/structural_complexity_and_conformational_dynamics_of_kras_protein": 1, "claim_path:daraxonrasib_clinical_trial_outcomes": 4, "claim_path:daraxonrasib_drug_development": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/biomarkers_predicting_response_to_daraxonrasib_therapy": 2, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/clinical_trial_results_demonstrating_daraxonrasib_efficacy": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/combination_therapies_involving_daraxonrasib_for_enhanced_survival": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/comparison_of_daraxonrasib_with_existing_pancreatic_cancer_treatments": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/future_directions_and_research_in_daraxonrasib_based_therapies": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/mechanism_of_action_of_daraxonrasib_in_pancreatic_cancer": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/pharmacokinetics_and_dosage_optimization_of_daraxonrasib": 4, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/resistance_mechanisms_to_daraxonrasib_in_pancreatic_cancer_cells": 3, "claim_path:daraxonrasib_extends_pancreatic_cancer_survival/side_effects_and_safety_profile_of_daraxonrasib": 2, "claim_path:daraxonrasib_s_manageable_side_effects": 3, "claim_path:daraxonrasib_targeting_kras_protein": 4, "claim_path:daraxonrasib_targeting_kras_protein/biomarker_development_for_predicting_response_to_daraxonrasib": 3, "claim_path:daraxonrasib_targeting_kras_protein/clinical_trial_results_of_daraxonrasib_targeting_kras_mutations": 4, "claim_path:daraxonrasib_targeting_kras_protein/combination_therapies_involving_daraxonrasib_for_enhanced_kras_inhibition": 3, "claim_path:daraxonrasib_targeting_kras_protein/efficacy_of_daraxonrasib_in_kras_driven_cancers": 4, "claim_path:daraxonrasib_targeting_kras_protein/mechanism_of_action_of_daraxonrasib_on_kras_protein": 4, "claim_path:daraxonrasib_targeting_kras_protein/pharmacokinetics_and_pharmacodynamics_of_daraxonrasib": 4, "claim_path:daraxonrasib_targeting_kras_protein/resistance_mechanisms_to_daraxonrasib_in_kras_mutant_tumors": 3, "claim_path:daraxonrasib_targeting_kras_protein/safety_profile_and_adverse_effects_of_daraxonrasib_treatment": 4, "claim_path:daraxonrasib_targeting_kras_protein/structural_interaction_between_daraxonrasib_and_kras_mutants": 3, "claim_path:innovative_drug_screening_methods": 4, "claim_path:kras_gene_mutations_and_cancer": 4, "claim_path:kras_gene_mutations_and_cancer/diagnostic_techniques_for_detecting_kras_gene_mutations": 3, "claim_path:kras_gene_mutations_and_cancer/molecular_mechanisms_of_kras_gene_mutations_in_oncogenesis": 4, "claim_path:kras_gene_mutations_and_cancer/prognostic_significance_of_kras_mutations_in_cancer_patients": 4, "claim_path:kras_gene_mutations_and_cancer/resistance_mechanisms_to_kras_targeted_therapies": 3, "claim_path:kras_gene_mutations_and_cancer/therapeutic_strategies_targeting_kras_mutant_cancers": 4, "claim_path:kras_protein_as_cancer_growth_driver": 4, "claim_path:kras_protein_as_cancer_growth_driver/challenges_in_targeting_kras_for_cancer_therapy": 4, "claim_path:kras_protein_as_cancer_growth_driver/downstream_signaling_pathways_activated_by_mutant_kras": 4, "claim_path:kras_protein_as_cancer_growth_driver/impact_of_kras_driven_metabolic_reprogramming_in_cancer_cells": 4, "claim_path:kras_protein_as_cancer_growth_driver/molecular_structure_and_function_of_kras_protein": 3, "claim_path:kras_protein_as_cancer_growth_driver/resistance_mechanisms_to_kras_targeted_treatments": 3, "claim_path:metastatic_pancreatic_cancer_treatment": 4, "claim_path:metastatic_pancreatic_cancer_treatment/chemotherapy_regimens_for_metastatic_pancreatic_cancer": 4, "claim_path:metastatic_pancreatic_cancer_treatment/immunotherapy_approaches_in_advanced_pancreatic_cancer": 4, "claim_path:metastatic_pancreatic_cancer_treatment/management_of_treatment_related_side_effects_and_toxicities": 4, "claim_path:metastatic_pancreatic_cancer_treatment/personalized_medicine_and_genetic_profiling_in_treatment_selection": 4, "claim_path:metastatic_pancreatic_cancer_treatment/radiation_therapy_applications_and_protocols": 4, "claim_path:metastatic_pancreatic_cancer_treatment/supportive_care_and_symptom_management_strategies": 4, "claim_path:metastatic_pancreatic_cancer_treatment/targeted_therapy_options_and_biomarkers": 4, "claim_path:molecular_screening_for_kras_binding": 4, "claim_path:molecular_screening_for_kras_binding/biophysical_methods_for_detecting_kras_ligand_interactions": 3, "claim_path:molecular_screening_for_kras_binding/cell_based_assays_for_functional_validation_of_kras_binders": 2, "claim_path:molecular_screening_for_kras_binding/challenges_in_screening_for_kras_g12c_specific_inhibitors": 4, "claim_path:molecular_screening_for_kras_binding/fluorescence_polarization_assays_in_kras_binding_studies": 3, "claim_path:molecular_screening_for_kras_binding/fragment_based_drug_discovery_targeting_kras": 4, "claim_path:molecular_screening_for_kras_binding/high_throughput_screening_techniques_for_kras_inhibitors": 2, "claim_path:molecular_screening_for_kras_binding/structure_based_virtual_screening_of_kras_binding_compounds": 4, "claim_path:molecular_screening_for_kras_binding/surface_plasmon_resonance_applications_in_kras_screening": 4, "claim_path:overcoming_decades_of_drug_discovery_failures": 4, "claim_path:pancreatic_lung_and_colon_cancer_linkage": 4, "claim_path:patient_tumor_shrinkage_and_survival": 4, "claim_path:patient_tumor_shrinkage_and_survival/biomarkers_predictive_of_tumor_response_and_survival": 4, "claim_path:patient_tumor_shrinkage_and_survival/correlation_between_tumor_shrinkage_and_overall_survival_rates": 4, "claim_path:patient_tumor_shrinkage_and_survival/imaging_techniques_for_monitoring_tumor_shrinkage_during_treatment": 3, "claim_path:patient_tumor_shrinkage_and_survival/influence_of_tumor_microenvironment_on_treatment_induced_shrinkage": 3, "claim_path:patient_tumor_shrinkage_and_survival/mechanisms_of_tumor_shrinkage_in_response_to_chemotherapy": 4, "claim_path:potential_applications_in_lung_and_colon_cancers": 4 }, "episode_count": 1, "event_count": 360, "incompatible_restrictions": 7, "learned_overlap_edge_count": 0, "local_psr_count": 19, "mean_events_per_episode": 360.0, "mean_glue_loss": 0.02160652944038903, "pairwise_restriction_count": 0, "review_chart_event_counts": {}, "root_restriction_count": 18, "sentiment_counts": { "adverse effects on normal tissue, improving the safety profile of the treatment": 1, "cancer cell death": 1, "cancer cell survival by inhibiting the kras-driven tumor growth": 1, "cancer cell survival, thereby increasing patient survival rates": 1, "cancer cells to develop resistance mechanisms that reduce the drug's long-term effectiveness": 1, "cancer cells to sustain uncontrolled growth despite daraxonrasib treatment": 1, "cancer progression by continuously driving signals for cell proliferation in pancreatic tumors": 1, "cancer progression by continuously driving tumor growth": 2, "cancer progression by continuously driving tumor growth in pancreatic cancer": 1, "cancer progression by continuously signaling cells to proliferate": 1, "cancer progression by driving continuous cell proliferation": 1, "cancer progression by driving continuous tumor cell proliferation": 3, "cancer progression by driving continuous tumor growth": 1, "cancer progression by driving the proliferation of tumor cells": 1, "cancer progression by enhancing the energy supply and biosynthetic processes necessary for tumor survival and expansion": 1, "cancer progression by increasing the proliferative capacity of cancer cells through enhanced nutrient utilization and energy production": 1, "cancer progression by inhibiting the permanently active kras protein caused by kras gene mutations": 1, "cancer progression by selectively killing cancer cells driven by active kras mutations": 1, "cancer progression by selectively killing cancer cells with kras mutations while sparing normal tissue": 1, "cancer progression in advanced pancreatic cancer patients": 1, "cancer progression in metastatic pancreatic cancer patients": 1, "cancer progression more effectively than existing pancreatic cancer treatments by targeting the previously undruggable kras mutations": 1, "cancer progression without targeted inhibition": 1, "cancer progression, thereby increasing the overall benefits of supportive care strategies": 1, "challenges in delivering kras-targeting agents into tumor cells": 1, "challenges in designing selective inhibitors, which increases the risk of toxicity and off-target effects in kras-targeted therapies": 1, "challenges in drug development that affect the off-target effects and side effects of kras-targeted treatments": 1, "challenges in targeting kras, which influences the development of mutation-specific therapies that reduce cancer progression": 1, "decreased severity of symptoms requiring supportive care in metastatic pancreatic cancer": 1, "decreased uncontrolled cell growth": 2, "decreased uncontrolled cell growth in cancer patients": 1, "differential tumor responses, which increases the accuracy of biomarker development for predicting patient outcomes": 1, "difficulties in designing molecules that can selectively bind and inhibit its function": 1, "downstream signaling pathways that bypass daraxonrasib inhibition, promoting resistance mechanisms in pancreatic cancer cells": 1, "drug resistance by selectively killing cancer cells driven by kras mutations": 1, "drug resistance mechanisms by binding to the kras protein and inhibiting its permanently active state in pancreatic cancer cells": 1, "enhanced immune system recognition of cancer cells and increases the effectiveness of immunotherapy approaches": 1, "enhanced inhibition of kras protein activity, resulting in greater tumor shrinkage": 1, "enhanced survival rates by targeting kras-driven tumor growth more effectively": 1, "extended patient survival": 1, "extended patient survival by reducing cancer progression more effectively than daraxonrasib alone": 1, "failures in traditional drug development by preventing effective binding of therapeutic molecules": 1, "failures in traditional drug development methods targeting kras-driven tumors": 1, "greater integration of artificial intelligence in treatment planning to optimize patient outcomes": 1, "improved patient survival, which increases the demand for precise treatment planning": 1, "improved survival outcomes": 1, "improved symptom management and enhanced effectiveness of supportive care in metastatic pancreatic cancer patients": 1, "improved understanding of kras-driven tumor biology, which influences the identification of early detection biomarkers for pancreatic cancer": 1, "increased drug efficacy and prolonged survival rates in patients treated with daraxonrasib": 1, "increased overall survival rates in pancreatic cancer patients": 1, "increased research efforts in developing early detection biomarkers": 1, "increased survival in pancreatic cancer patients": 1, "ineffective treatment by enabling personalized therapy that directly affects tumor shrinkage and patient survival": 1, "inhibition of the kras protein, which leads to tumor shrinkage in pancreatic cancer patients": 2, "inhibition of the kras protein, which reduces cancer progression by causing tumor shrinkage": 1, "inhibition of the kras protein, which reduces tumor size in pancreatic cancer patients": 1, "inhibition of the kras protein, which reduces uncontrolled cell growth in metastatic pancreatic cancer": 1, "its distribution and metabolism in patients with kras-mutant tumors": 1, "its membrane association by determining its proximity to the plasma membrane where kras becomes active": 1, "limitations of current screening methods for kras inhibitors": 1, "manageable side effects by inhibiting the kras protein in cancer therapy": 1, "manageable side effects during treatment": 1, "manageable side effects in metastatic pancreatic cancer patients": 1, "manageable side effects in pancreatic cancer patients": 1, "manageable side effects in patients with kras-mutant pancreatic cancer": 1, "manageable side effects, thereby affecting the overall management of toxicities in metastatic pancreatic cancer patients": 1, "metabolic reprogramming that drives uncontrolled cell growth in cancer progression": 1, "metabolic reprogramming that increases cancer cell growth and proliferation": 1, "more accurate identification of effective kras inhibitors during molecular screening": 1, "more accurate identification of kras mutations, which affects the diagnosis and monitoring of cancer progression": 1, "more effective personalization of daraxonrasib use in pancreatic cancer patients": 1, "off-target effects and improves patient survival outcomes": 1, "overall survival rates in these patients": 1, "pancreatic cancer patient survival by selectively inhibiting the kras protein and prolonging life": 1, "pancreatic cancer patient survival by selectively inhibiting the kras protein, leading to tumor shrinkage": 1, "pancreatic cancer progression": 1, "pancreatic cancer survival by binding to the mutated kras protein, leading to tumor shrinkage and prolonged patient life": 1, "pancreatic tumor growth": 1, "pancreatic tumor growth and prolongs patient survival": 1, "past drug development failures": 2, "past drug development failures for kras g12c-specific inhibitors": 1, "past drug development failures targeting kras": 4, "past drug development failures targeting kras-driven cancers": 1, "past drug development failures targeting the protein": 1, "past drug development failures, which influences the emergence of alternative drug resistance mechanisms in kras-mutant cancers": 1, "past failures in drug development because traditional drugs cannot effectively bind and inhibit kras": 1, "patient survival": 5, "patient survival by inhibiting the active kras protein in pancreatic cancer cells": 1, "patient survival by selectively killing cancer cells": 1, "patient survival by selectively killing cancer cells while sparing normal tissue": 5, "patient survival by shrinking tumors": 1, "patient survival in pancreatic cancer": 1, "patient survival rates in pancreatic cancer treatment": 1, "patient survival when used in combination chemotherapy regimens": 1, "pharmacodynamics by selectively killing cancer cells and increasing patient survival": 1, "prolonged patient life in pancreatic cancer by selectively inhibiting the kras protein": 1, "prolonged patient survival following pancreatic cancer surgery": 1, "radiation therapy outcomes by inhibiting kras, leading to tumor shrinkage and potentially enhancing the response to radiation": 1, "resistance mechanisms that reduce the effectiveness of kras inhibitors in cancer cells": 1, "selective killing of cancer cells": 1, "side effects in pancreatic cancer patients": 1, "side effects, leading to enhanced patient tolerance and prolonged survival outcomes": 1, "survival by selectively inhibiting the mutant kras protein in pancreatic cancer patients": 1, "survival by selectively killing cancer cells while sparing normal tissue": 1, "survival in cancer patients": 1, "survival in cancer patients by selectively inhibiting kras protein activity": 1, "survival in cancer patients with kras mutations": 1, "survival in pancreatic cancer patients": 4, "survival in pancreatic cancer patients by selectively killing cancer cells while sparing normal tissue": 1, "survival in patients with kras-mutant cancers": 1, "survival in patients with kras-mutant pancreatic cancer": 1, "survival in patients with pancreatic, lung, and colon cancers": 1, "survival rates by reducing tumor progression and causing manageable side effects in patients undergoing radiation therapy": 1, "survival rates by selectively killing cancer cells while sparing normal tissue, resulting in prolonged patient life": 1, "survival rates in pancreatic cancer patients": 1, "survival rates in pancreatic cancer patients by preventing uncontrolled cell growth and cancer progression": 1, "survival rates in patients with kras-mutant pancreatic, lung, and colon cancers by selectively killing cancer cells while sparing normal tissue": 1, "survival specifically in metastatic pancreatic cancer patients with kras mutations identified through personalized genetic profiling": 1, "survival time by selectively killing cancer cells driven by kras mutations": 1, "survival time in pancreatic cancer patients": 1, "sustained cancer cell growth despite kras inhibition by daraxonrasib": 1, "the ability of conventional drugs to inhibit kras, thereby causing continued cancer progression": 1, "the ability of conventional molecular screening methods to identify effective kras inhibitors": 1, "the ability of daraxonrasib to consistently bind and inhibit kras across all cancer cells, leading to incomplete tumor shrinkage": 1, "the ability of traditional drugs to inhibit kras, leading to challenges in creating effective cancer therapies": 1, "the ability to monitor patient responses to daraxonrasib, thereby affecting clinical decisions on treatment continuation or adjustment": 1, "the ability to target previously undruggable kras binding sites, overcoming challenges in developing selective inhibitors": 1, "the ability to target previously undruggable kras mutations, resulting in tumor shrinkage and extended survival in pancreatic cancer patients": 1, "the accuracy of biomarkers in predicting treatment response": 1, "the accuracy of diagnostic techniques by enabling selective identification of cancerous cells harboring these mutations": 1, "the activation of alternative cancer growth pathways that cause treatment resistance": 1, "the activation of downstream signaling pathways in cancer cells": 1, "the activity of the permanently active kras, leading to tumor shrinkage in kras-driven cancers": 1, "the availability of druggable pockets on kras, influencing past drug development failures": 1, "the balance between therapeutic efficacy and tolerability by causing side effects that are clinically acceptable": 1, "the balance between tumor targeting and the emergence of toxic side effects": 1, "the continuous stimulation of downstream signaling pathways that promote tumor growth": 1, "the detection of molecular interactions that bind to kras protein": 1, "the development of biomarkers by providing a targeted mechanism against kras protein that allows identification of molecular signatures predicting therapeutic response": 1, "the development of biophysical methods for detecting kras-ligand interactions by enabling the discovery of effective kras inhibitors": 1, "the development of daraxonrasib to balance efficacy and tolerability, causing side effects to remain manageable in patients": 1, "the development of daraxonrasib, a drug that binds the kras protein and inhibits its cancer-promoting activity": 1, "the development of daraxonrasib, which selectively kills cancer cells and reduces tumor growth in pancreatic cancer patients": 1, "the development of drugs like daraxonrasib, which improves tumor shrinkage and enhances patient response to immunotherapy in pancreatic cancer": 1, "the development of effective car-t cell therapy drugs": 1, "the development of resistance mechanisms by selectively targeting the kras protein, which may lead to adaptive changes in kras-mutant tumors": 1, "the development of targeted drugs like daraxonrasib that reduce tumor growth and improve patient survival": 1, "the development of targeted drugs like daraxonrasib that selectively inhibit mutant kras proteins and reduce tumor growth": 1, "the difficulty of designing effective inhibitors, reducing the success rate of past drug development efforts": 1, "the difficulty of designing effective kras-targeting agents": 1, "the difficulty of designing inhibitors that do not affect normal cells, leading to off-target effects and toxicity": 1, "the difficulty of designing selective inhibitors and thereby influences the toxicity profile of kras-targeted therapies": 1, "the discovery of inhibitors like daraxonrasib, which reduces tumor growth and improves patient survival": 1, "the discovery of molecules that selectively inhibit kras, affecting cancer cell growth and patient survival": 1, "the drug\u2019s ability to reduce kras-driven cancer progression and extend pancreatic cancer patient survival": 1, "the effectiveness of chemotherapy regimens by driving tumor growth that traditional treatments struggle to control": 1, "the effectiveness of combination therapies by selectively inhibiting the kras protein, leading to enhanced kras inhibition in tumor cells": 1, "the effectiveness of daraxonrasib by affecting the accessibility and binding of the drug to the kras protein in cancer cells": 1, "the effectiveness of daraxonrasib by allowing alternative pathways to drive cancer cell growth despite kras inhibition": 1, "the effectiveness of daraxonrasib in causing tumor shrinkage in pancreatic cancer patients": 1, "the effectiveness of daraxonrasib treatment by identifying patients whose tumors have the targetable kras protein stuck in the \u201con\u201d position": 1, "the effectiveness of daraxonrasib treatment, allowing tumor progression to continue": 1, "the effectiveness of delivering kras-targeting agents into tumor cells": 1, "the effectiveness of past drug discovery approaches targeting kras inhibitors": 1, "the effectiveness of radiation therapy protocols in metastatic pancreatic cancer treatment": 1, "the effectiveness of targeting kras mutations, which influences improved surgical outcomes": 1, "the effectiveness of therapeutics in delivering treatment to kras-driven tumors": 1, "the effectiveness of traditional drugs, causing drug resistance in pancreatic cancer therapy": 1, "the effectiveness of traditional inhibitors, influencing resistance mechanisms in cancer cells treated with daraxonrasib": 1, "the effectiveness of treatment by overcoming drug resistance mechanisms": 1, "the effectiveness of treatment-induced tumor shrinkage": 1, "the effectiveness of treatments by enabling drugs like daraxonrasib to selectively inhibit the active kras protein": 1, "the efficacy of combination chemotherapy regimens by selectively inhibiting the kras protein, leading to tumor shrinkage": 1, "the efficacy of daraxonrasib by causing variability in kras mutations and protein activity within pancreatic tumors": 1, "the efficacy of daraxonrasib by enabling cancer cells to resume uncontrolled growth despite treatment": 1, "the efficacy of kras-targeted therapies by causing variable kras protein activity within different tumor cell populations": 1, "the efficacy of treatment and extends patient survival": 1, "the failure of traditional screening methods for kras inhibitors": 1, "the identification of compounds like daraxonrasib that can selectively bind kras despite these challenges": 1, "the identification of compounds that bind specifically to the kras protein": 1, "the identification of compounds that bind to the kras protein by revealing novel binding pockets on the previously undruggable target": 1, "the identification of compounds that effectively inhibit the kras protein": 1, "the identification of daraxonrasib as a ligand that binds to kras": 1, "the identification of daraxonrasib as a molecule that binds kras": 1, "the identification of daraxonrasib as a molecule that binds kras, enabling targeted inhibition of the protein": 1, "the identification of daraxonrasib as a molecule that selectively inhibits kras": 1, "the identification of daraxonrasib molecules that bind specifically to kras proteins": 1, "the identification of daraxonrasib, a compound that binds the kras protein": 1, "the identification of daraxonrasib, a kras g12c-specific inhibitor that effectively binds the kras protein": 1, "the identification of daraxonrasib, a molecule that selectively inhibits kras": 1, "the identification of daraxonrasib, which binds kras and reduces tumor growth in pancreatic cancer": 1, "the identification of effective kras inhibitors like daraxonrasib": 1, "the identification of effective molecules like daraxonrasib that bind kras and inhibit tumor growth": 1, "the identification of molecules like daraxonrasib that can bind to kras, overcoming previous drug development failures": 1, "the identification of molecules that selectively bind to kras, enabling the development of targeted cancer therapies": 1, "the identification of patients whose cancer cells have permanently active kras proteins, influencing the selection of daraxonrasib treatment": 1, "the identification of potential kras inhibitors by enabling the discovery of molecules like daraxonrasib that specifically bind to kras": 1, "the inhibition of the kras protein in lung cancer patients with kras mutations, which reduces uncontrolled cell growth": 1, "the inhibition of the kras protein, causing tumor shrinkage in kras-mutant cancers": 1, "the inhibition of the kras protein, which increases tumor shrinkage in metastatic pancreatic cancer patients": 1, "the inhibition of the kras protein, which reduces tumor growth in pancreatic cancer patients": 1, "the inhibition of the kras protein, which reduces uncontrolled cell growth in pancreatic cancer": 1, "the inhibition of the kras protein, which reduces uncontrolled cell growth in pancreatic cancer cells": 1, "the inhibition of the kras protein, which reduces uncontrolled cell growth in pancreatic cancer patients with kras mutations": 1, "the kras protein to remain permanently active, which leads to uncontrolled cell growth": 1, "the kras protein's activity by inhibiting its permanently active state caused by mutations": 1, "the likelihood of selecting kras-targeting drugs that lead to tumor shrinkage and improved patient survival": 1, "the likelihood that tumors develop mutations or pathways that reduce drug efficacy and promote resistance": 1, "the precision of daraxonrasib targeting kras mutations in pancreatic cancer, leading to enhanced tumor shrinkage": 1, "the progression of pancreatic cancer": 1, "the protein to lack druggable binding pockets": 1, "the risk of ineffective treatment continuation, thereby increasing the likelihood of prolonged patient survival during daraxonrasib therapy": 1, "the safety profile of the treatment, leading to prolonged patient life despite adverse effects": 1, "the selection of diagnostic techniques by increasing the need for molecular screening methods that can detect specific genetic alterations": 1, "the selection of pancreatic cancer cells with mutations that reduce drug binding to kras": 1, "the selective binding of daraxonrasib to the kras protein": 1, "the severity and frequency of toxicities during daraxonrasib therapy": 1, "the severity of side effects, leading to their manageability in pancreatic cancer patients": 1, "the severity of treatment-related toxicities during daraxonrasib therapy": 1, "the time required to discover daraxonrasib by rapidly testing large libraries of molecules for kras binding affinity": 1, "the tumor microenvironment by inhibiting kras protein activity, leading to increased tumor shrinkage and extended patient survival": 1, "the use of artificial intelligence by providing new molecular targets that ai algorithms can analyze for personalized treatment strategies": 1, "therapies to affect non-cancerous cells, thereby influencing adverse side effects and limiting treatment safety": 1, "this activity by selectively killing cancer cells, thereby increasing patient survival": 1, "this effect by selectively killing cancer cells": 1, "timely adjustments in therapy that improve survival outcomes": 1, "traditional drug discovery methods to be ineffective against targeting the protein": 1, "traditional drug discovery methods to be ineffective in designing kras inhibitors": 1, "traditional kras inhibitors to bind non-specifically, which increases off-target effects and toxicity": 1, "treatment efficacy in pancreatic cancer patients": 1, "tumor growth": 1, "tumor growth and prolongs survival in pancreatic cancer patients with specific kras mutations identified through genetic profiling": 1, "tumor growth by binding to the kras protein and inhibiting its permanently active state caused by kras mutations": 1, "tumor growth by inhibiting the permanently active kras signaling in cancer cells": 1, "tumor growth by inhibiting the permanently active kras signaling that drives pancreatic cancer progression": 1, "tumor growth more effectively than daraxonrasib alone, thereby improving cancer treatment outcomes": 1, "tumor progression by inhibiting kras activity, which affects the molecular profiles used to develop early detection biomarkers": 1, "tumor shrinkage": 4, "tumor shrinkage and extended patient survival compared to existing pancreatic cancer treatments that do not effectively target kras mutations": 1, "tumor shrinkage and extended patient survival in clinical trials": 1, "tumor shrinkage and extended survival in pancreatic cancer patients": 4, "tumor shrinkage and extends survival in pancreatic cancer patients": 1, "tumor shrinkage and extends survival in pancreatic cancer patients by selectively killing cancer cells while sparing normal tissue": 1, "tumor shrinkage and improved patient survival": 1, "tumor shrinkage and improved survival in colon cancer patients": 1, "tumor shrinkage and improved survival in metastatic pancreatic cancer patients with kras protein mutations": 1, "tumor shrinkage and improved survival in pancreatic cancer patients": 2, "tumor shrinkage and improved survival in pancreatic cancer patients with kras mutations": 1, "tumor shrinkage and improves patient survival in lung cancer": 1, "tumor shrinkage and improves patient survival, thereby affecting the need and timing for supportive care and symptom management strategies": 1, "tumor shrinkage and increases patient survival": 1, "tumor shrinkage and increases patient survival in advanced pancreatic cancer": 1, "tumor shrinkage and increases patient survival in pancreatic cancer": 2, "tumor shrinkage and increases survival in pancreatic cancer patients": 1, "tumor shrinkage and increases survival in pancreatic cancer patients with kras mutations": 1, "tumor shrinkage and increases survival time in pancreatic cancer patients": 1, "tumor shrinkage and prolonged patient survival by selectively killing cancer cells while sparing normal tissue": 1, "tumor shrinkage and prolonged patient survival in kras-driven cancers": 1, "tumor shrinkage by selectively inhibiting the kras protein that drives cancer growth in metastatic pancreatic cancer patients": 1, "tumor shrinkage in cancer patients": 1, "tumor shrinkage in metastatic pancreatic cancer patients": 2, "tumor shrinkage in pancreatic cancer": 1, "tumor shrinkage in pancreatic cancer patients": 10, "tumor shrinkage in pancreatic cancer patients by simultaneously targeting kras-driven cancer cells and enhancing cytotoxic effects": 1, "tumor shrinkage in pancreatic cancer patients with kras mutations": 2, "tumor shrinkage, which informs the design of car-t therapies targeting similar oncogenic drivers": 1, "tumor shrinkage, which reduces drug clearance variability and stabilizes pharmacodynamic responses": 1, "tumor size by inhibiting the kras protein": 1, "tumor size by inhibiting the kras protein, which drives cancer cell growth": 1, "uncontrolled cancer cell growth and influences the effectiveness of immunotherapy approaches": 1, "uncontrolled cancer cell growth and progression in metastatic pancreatic cancer": 1, "uncontrolled cancer cell growth and tumor progression": 1, "uncontrolled cell growth": 11, "uncontrolled cell growth and cancer progression": 3, "uncontrolled cell growth and cancer progression despite daraxonrasib treatment": 1, "uncontrolled cell growth and cancer progression despite kras-targeted therapies": 1, "uncontrolled cell growth and cancer progression in metastatic pancreatic cancer": 1, "uncontrolled cell growth and cancer progression in pancreatic cancer": 1, "uncontrolled cell growth and cancer progression in pancreatic cancer patients": 1, "uncontrolled cell growth and cancer progression in pancreatic, lung, and colon cancers": 1, "uncontrolled cell growth and contributes to pancreatic cancer progression": 1, "uncontrolled cell growth by continuously stimulating downstream signaling pathways": 1, "uncontrolled cell growth by inhibiting the permanently active kras caused by mutations": 1, "uncontrolled cell growth by inhibiting the permanently active kras protein": 1, "uncontrolled cell growth by inhibiting the permanently active kras protein caused by kras mutations": 1, "uncontrolled cell growth by persistently activating signaling pathways involved in cancer progression": 1, "uncontrolled cell growth by selectively inhibiting the kras protein in kras-mutant pancreatic cancer cells": 1, "uncontrolled cell growth caused by kras mutations, thereby increasing patient survival rates": 1, "uncontrolled cell growth in cancer cells": 2, "uncontrolled cell growth in colon cancer": 1, "uncontrolled cell growth in kras-mutated cancers": 1, "uncontrolled cell growth in metastatic pancreatic cancer": 1, "uncontrolled cell growth in pancreatic cancer": 7, "uncontrolled cell growth in pancreatic cancer tumors": 1, "uncontrolled cell growth in pancreatic cancer, leading to tumor shrinkage": 1, "uncontrolled cell growth that reduces the effectiveness of daraxonrasib in targeted cancer therapy": 1, "uncontrolled cell growth, thereby increasing survival in these patients": 1, "uncontrolled cell growth, which drives cancer progression": 1, "uncontrolled cell growth, which enhances the therapeutic impact of chemotherapy in pancreatic cancer patients": 1, "uncontrolled pancreatic tumor growth": 1, "variation in the protein structure, which reduces the effectiveness of mutation-specific inhibitors": 1, "varying degrees of tumor shrinkage": 1 }, "sheaf_object_count": 19, "split_counts": { "unknown": 1 }, "tense_gluing_overlaps": 0, "top_aspects": { "affects": 7, "causes": 27, "increases": 86, "influences": 33, "leads_to": 146, "reduces": 61 }, "twm_objective_glue_term": 0.3734752147569597 } }, "label": "Nytimes Kras PDF", "query": "Analyze the document in /Users/sridharmahadevan/Desktop/PDFs/NYTimes_KRAS.pdf", "reasons": [ "corpus has 7 divergent restriction check(s)" ], "recommended_actions": [ { "action": "inspect_overlap_divergence", "label": "Inspect corpus overlap divergence", "rationale": "corpus has 7 divergent restriction check(s)", "target": { "context_id": "corpus" } } ], "schema_version": "prometheus.persistent_state.v1", "source_artifacts": { "world_model_path": "/Users/sridharmahadevan/Downloads/mac-cech_homology_GT/Prometheus_v1/runs/prometheus_gui/run-0001-analyze-the-document-in-users-sridharmahadevan-d-fe37f5efaf/democritus/prometheus_claims_twm/prometheus_world_model.json" }, "state_kind": "prometheus_persistent_world_state" }